CN115052631A - 用于增强免疫及肿瘤治疗的方法 - Google Patents

用于增强免疫及肿瘤治疗的方法 Download PDF

Info

Publication number
CN115052631A
CN115052631A CN202080095859.9A CN202080095859A CN115052631A CN 115052631 A CN115052631 A CN 115052631A CN 202080095859 A CN202080095859 A CN 202080095859A CN 115052631 A CN115052631 A CN 115052631A
Authority
CN
China
Prior art keywords
tumor
lesion
cancer
cells
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080095859.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·加西亚-古斯曼
J·方
A·瑟尼
M·许
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rakuten Medical Inc
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of CN115052631A publication Critical patent/CN115052631A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080095859.9A 2019-12-06 2020-12-04 用于增强免疫及肿瘤治疗的方法 Pending CN115052631A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945053P 2019-12-06 2019-12-06
US62/945,053 2019-12-06
PCT/US2020/063444 WO2021113734A1 (en) 2019-12-06 2020-12-04 Methods for enhancing immunity and tumor treatment

Publications (1)

Publication Number Publication Date
CN115052631A true CN115052631A (zh) 2022-09-13

Family

ID=73856374

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080095859.9A Pending CN115052631A (zh) 2019-12-06 2020-12-04 用于增强免疫及肿瘤治疗的方法

Country Status (6)

Country Link
US (1) US20230028062A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069300A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023505222A (cg-RX-API-DMAC7.html)
CN (1) CN115052631A (cg-RX-API-DMAC7.html)
TW (1) TW202133886A (cg-RX-API-DMAC7.html)
WO (1) WO2021113734A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364238A (zh) * 2022-08-16 2022-11-22 山东大学 一种阿特珠单抗-mmad结合物及其制备方法与应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
WO2022182483A1 (en) * 2021-02-02 2022-09-01 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
CA3252736A1 (en) * 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-PD-L1 (Programmed Death-Ligand 1) Antibody Molecules, Coding Polynucleotides, and Methods of Use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
ES2992591T3 (en) * 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
ES2999358T3 (en) * 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
CN109863346A (zh) 2016-10-25 2019-06-07 乐天医药生技股份有限公司 用于光免疫治疗的光漫射装置
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
JP2020508323A (ja) * 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
US12704501B2 (en) * 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
CN114423453A (zh) * 2019-07-30 2022-04-29 乐天医药生技股份有限公司 使用偶联的抗cd25酞菁和抗pd1的基于光化学的癌症疗法近红外(nir)光免疫疗法(pit)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364238A (zh) * 2022-08-16 2022-11-22 山东大学 一种阿特珠单抗-mmad结合物及其制备方法与应用
CN115364238B (zh) * 2022-08-16 2024-02-02 山东大学 一种阿特珠单抗-mmad结合物及其制备方法与应用

Also Published As

Publication number Publication date
US20230028062A1 (en) 2023-01-26
EP4069300A1 (en) 2022-10-12
WO2021113734A1 (en) 2021-06-10
JP2023505222A (ja) 2023-02-08
TW202133886A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
KR102595561B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
JP7324710B2 (ja) 肺癌の処置のための抗pd-1抗体
TWI663983B (zh) 用於治療癌症之pd-1拮抗劑及vegfr抑制劑之組合
RU2766890C2 (ru) Комбинированные способы лечения антагонистами pd-l1
CN110869765A (zh) 组合疗法
US20230028062A1 (en) Methods for enhancing immunity and tumor treatment
JP2022515188A (ja) がん治療のための組成物および方法
EP3896089A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
CN111278448A (zh) 用于治疗肝癌的组合物和方法
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
US20210277135A1 (en) Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
CN112638392A (zh) 组合疗法
WO2020049534A1 (en) Sting agonist and combination therapy thereof for the treatment of cancer
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
RU2802962C2 (ru) Композиции и способы лечения рака печени
HK40051088A (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
BR112017027026B1 (pt) Usos de um antagonista de pd-l1 e de um inibidor de vegfr, medicamentos e kits compreendendo os mesmos
EA049388B1 (ru) Способы лечения базально-клеточной карциномы путем введения антитела или его антигенсвязывающего фрагмента, специфически связывающихся с pd-1
EA045900B1 (ru) Комбинация антител против pd-1 и облучения для лечения злокачественной опухоли

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination